Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: A meta-analysis stratified by treatment

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 107-113.e5

  Turner, Steve ^a   Francis, Ben ^b   Vijverberg, Susanne ^c   Pino Yanes, Maria ^d,e   Maitland van der Zee, Anke H ^c   Basu, Kaninika ^f   Bignell, Lauren ^f   Mukhopadhyay, Somnath ^f,g   Tavendale, Roger ^g   Palmer, Colin ^g   Hawcutt, Daniel ^b   Pirmohamed, Munir ^b   Burchard, Esteban G ^h   Lipworth, Brian ^g  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^f ROYAL ALEXANDRA CHILDREN S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenergic receptors; asthma; child; disease exacerbation; therapeutics

Indexed keywords

AMINO ACID; ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DNA; GLYCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA 2 AGONIST; SHORT ACTING BETA AGONIST; STEROID; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; CODON;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASTHMA; CAUCASIAN; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DNA EXTRACTION; DRUG EXPOSURE; FEMALE; GENE FREQUENCY; GENOTYPE; HISPANIC; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY; NORTHERN EUROPEAN; ODDS RATIO; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; ADOLESCENT; CHEMISTRY; CODON; DISEASE COURSE; GENETICS; META ANALYSIS; PRESCHOOL CHILD;

ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALLELES; ANTI-ASTHMATIC AGENTS; ARGININE; ASTHMA; CHILD; CHILD, PRESCHOOL; CODON; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS;

EID: 84953231094     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.10.045     Document Type: Article

References (48)

1. 1 Lemanske, R.F. Jr., Mauger, D.T., Sorkness, C.A., Jackson, D.J., Boehmer, S.J., Martinez, F.D., et al. Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 362 (2010), 975–985.
2. 2 Szefler, S.J., Phillips, B.R., Martinez, F.D., Chinchilli, V.M., Lemanske, R.F., Strunk, R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005), 233–242.
3. 3 Palmer, C.N., Lipworth, B.J., Lee, S., Ismail, T., Macgregor, D.F., Mukhopadhyay, S., Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61 (2006), 940–944.
4. 4 Zuurhout, M.J., Vijverberg, S.J., Raaijmakers, J.A., Koenderman, L., Postma, D.S., Koppelman, G.H., et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics 14 (2013), 1965–1971.
5. 5 Basu, K., Palmer, C.N., Tavendale, R., Lipworth, B.J., Mukhopadhyay, S., Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol 124 (2009), 1188–1194.e3.
6. 6 Martinez, F.D., Graves, P.E., Baldini, M., Solomon, S., Erickson, R., Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 (1997), 3184–3188.
7. 7 Silverman, E.K., Kwiatkowski, D.J., Sylvia, J.S., Lazarus, R., Drazen, J.M., Lange, C., et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 112 (2003), 870–876.
8. 8 Turner, S.W., Genetic predictors of response to therapy in childhood asthma. Mol Diag Ther 13 (2009), 127–135.
9. 9 Finkelstein, Y., Bournissen, F.G., Hutson, J.R., Shannon, M., Polymorphism of the ADRB2 gene and response to inhaled beta-agonists in children with asthma: a meta-analysis. J Asthma 46 (2009), 900–905.
10. 10 Turner, S.W., Khoo, S.K., Laing, I.A., Palmer, L.J., Gibson, N.A., Rye, P., et al. beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy 34 (2004), 1043–1048.
11. 11 Carroll, C.L., Stoltz, P., Schramm, C.M., Zucker, A.R., Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 135 (2009), 1186–1192.
12. 12 Carroll, C.L., Sala, K.A., Zucker, A.R., Schramm, C.M., Beta-adrenergic receptor polymorphisms associated with length of ICU stay in pediatric status asthmaticus. Pediatr Pulmonol 47 (2012), 233–239.
13. 13 Carroll, C.L., Sala, K.A., Zucker, A.R., Schramm, C.M., beta2-adrenergic receptor haplotype linked to intubation and mechanical ventilation in children with asthma. J Asthma 49 (2012), 563–568.
14. 14 Giubergia, V., Gravina, L., Castanos, C., Chertkoff, L., Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. Ann Allergy Asthma Immunol 110 (2013), 156–160.
15. 15 Lipworth, B.J., Basu, K., Donald, H.P., Tavendale, R., Macgregor, D.F., Ogston, S.A., et al. Tailored second-line therapy in asthmatic children with the arg(16) genotype. Clin Sci 124 (2013), 521–528.
16. 16 Bleecker, E.R., Postma, D.S., Lawrance, R.M., Meyers, D.A., Ambrose, H.J., Goldman, M., Effect of ADRB2 polymorphisms on response to long acting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370 (2007), 2118–2125.
17. 17 Bleecker, E.R., Nelson, H.S., Kraft, M., Corren, J., Meyers, D.A., Yancey, S.W., et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 181 (2010), 676–687.
18. 18 Wechsler, M.E., Kunselman, S.J., Chinchilli, V.M., Bleecker, E., Boushey, H.A., Calhoun, W.J., et al. National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Effect of beta2-adrenergic receptor polymorphism on response to long acting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374 (2009), 1754–1764.
19. 19 Vijverberg, S.J., Koster, E.S., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J.A., et al. ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clin Exp Allergy 45 (2015), 1051–1059.
20. 20 Galanter, J.M., Gignoux, C.R., Torgerson, D.G., Roth, L.A., Eng, C., Oh, S.S., et al. Genome-wide association study and admixture mapping identify different asthma-associated loci in Latinos: the Genes-Environments and Admixture in Latino Americans study. J Allergy Clin Immunol 134 (2014), 295–305.
21. 21 Magi, R., Morris, A.P., GWAMA: software for genome-wide association meta-analysis. BMC Bioinformatics, 11, 2010, 288.
22. 22 Purcell, S., Cherny, S.S., Sham, P.C., Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003), 149–150.
23. 23 Hall, I.P., Blakey, J.D., Genetic association studies in thorax. Thorax 60 (2005), 357–359.
24. 24 Ortega, V.E., Meyers, D.A., Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol 133 (2014), 16–26.
25. 25 Lima, J.J., Thomason, D.B., Mohamed, M.H., Eberle, L.V., Self, T.H., Johnson, J.A., Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65 (1999), 519–525.
26. 26 Choudhry, S., Ung, N., Avila, P.C., Ziv, E., Nazario, S., Casal, J., et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 171 (2005), 563–570.
27. 27 Israel, E., Drazen, J.M., Liggett, S.B., Boushey, H.A., Cherniack, R.M., Chinchilli, V.M., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000), 75–80.
28. 28 Israel, E., Chinchilli, V.M., Ford, J.G., Boushey, H.A., Cherniack, R., Craig, T.J., et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004), 1505–1512.
29. 29 Taylor, D.R., Drazen, J.M., Herbison, G.P., Yandava, C.N., Hancox, R.J., Town, G.I., Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55 (2000), 762–767.
30. 30 Lee, D.K., Currie, G.P., Hall, I.P., Lima, J.J., Lipworth, B.J., The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 57 (2004), 68–75.
31. 31 British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma 2014. Available at: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/. Accessed June 2, 2015.
32. 32 Global Initiative for Asthma. Pocket guide for asthma management and prevention. Available at: http://www.ginasthma.org/documents/1. Accessed June 2, 2015.
33. 33 Vaessen-Verberne, A.A., van den Berg, N.J., van Nierop, J.C., Brackel, H.J., Gerrits, G.P., Hop, W.C., et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 182 (2010), 1221–1227.
34. 34 Lipworth, B., Beta-adrenoceptor genotype and bronchoprotective subsensitivity with long-acting beta-agonists in asthma. Am J Respir Crit Care Med 188 (2013), 1386–1387.
35. 35 Green, S.A., Turki, J., Bejarano, P., Hall, I.P., Liggett, S.B., Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13 (1995), 25–33.
36. 36 Currie, G.P., Lee, D.K., Haggart, K., Bates, C.E., Lipworth, B.J., Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 167 (2003), 1232–1238.
37. 37 Ortega, V.E., Hawkins, G.A., Moore, W.C., Hastie, A.T., Ampleford, E.J., Busse, W.W., et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med 2 (2014), 204–213.
38. 38 Turner, S., Thomas, M., von Ziegenweidt, J., Price, D., Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 94 (2009), 16–22.
39. 39 Lozano, P., Fishman, P., VonKorff, M., Hecht, J., Health care utilization and cost among children with asthma who were enrolled in a health maintenance organization. Pediatrics 99 (1997), 757–764.
40. 40 Wang, L.Y., Zhong, Y., Wheeler, L., Direct and indirect costs of asthma in school-age children. Prevent Chronic Dis, 2, 2005, A11.
41. 41 Lenney, W., The burden of pediatric asthma. Pediatr Pulmonol 15 (1997), 13–16.
42. 42 Kim, S.H., Ye, Y.M., Lee, H.Y., Sin, H.J., Park, H.S., Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 36 (2011), 399–405.
43. Palmer, C.N., Lipworth, B.J., Lee, S., Ismail, T., Macgregor, D.F., Mukhopadhyay, S., Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61 (2006), 940–944.
44. Nishimura, K.K., Galanter, J.M., Roth, L.A., Oh, S.S., Thakur, N., Nguyen, E.A., et al. Early-life air pollution and asthma risk in minority children. The GALA II and SAGE II studies. Am J Respir Crit Care Med 188 (2013), 309–318.
45. Alexander, D.H., Novembre, J., Lange, K., Fast model-based estimation of ancestry in unrelated individuals. Genome Res 19 (2009), 1655–1664.
46. Turner, S.W., Ayres, J.G., Macfarlane, T.V., Mehta, A., Mehta, G., Palmer, C.N., et al. A methodology to establish a database to study gene environment interactions for childhood asthma. BMC Med Res Methodol, 10, 2010, 107.
47. Koster, E.S., Raaijmakers, J.A., Koppelman, G.H., Postma, D.S., van der Ent, C.K., Koenderman, L., et al. Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort. Pharmacogenomics 10 (2009), 1351–1361.
48. Hawcutt, D.B., Jorgensen, A.L., Wallin, N., Thompson, B., Peak, M., Lacy, D., et al. Adrenal responses to a low dose short synacthen test in children with asthma. Clin Endocrinol (Oxf) 82 (2015), 648–656.